Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ESTA Stock Forecast 2026-2027
$86.59
Current Price
$2.55B
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ESTA Price Targets
+21.3%
To High Target of $105.00
+6.2%
To Median Target of $92.00
-3.0%
To Low Target of $84.00
ESTA Price Momentum
-1.6%
1 Week Change
+2.8%
1 Month Change
+94.9%
1 Year Change
+18.8%
Year-to-Date Change
-6.7%
From 52W High of $92.84
+159.6%
From 52W Low of $33.35
📊 TOP ANALYST CALLS
Did ESTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Establishment Labs is one of their latest high-conviction picks.
Latest ESTA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ESTA has a bullish consensus with a median price target of $92.00 (ranging from $84.00 to $105.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $86.59, the median forecast implies a 6.2% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESTA Analyst Ratings
8
Buy
1
Hold
0
Sell
ESTA Price Target Range
Low
$84.00
Average
$92.00
High
$105.00
Current: $86.59
Latest ESTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | Citigroup | Joanne Wuensch | Neutral | Maintains | $92.00 |
| May 7, 2026 | BTIG | Buy | Maintains | $N/A | |
| Apr 29, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 11, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 26, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 25, 2026 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Feb 25, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Feb 24, 2026 | Needham | Buy | Maintains | $N/A | |
| Feb 24, 2026 | BTIG | Buy | Maintains | $N/A | |
| Jan 12, 2026 | Needham | Buy | Reiterates | $N/A | |
| Dec 31, 2025 | BTIG | Buy | Maintains | $N/A | |
| Dec 17, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 17, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Dec 17, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Dec 11, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Dec 10, 2025 | Needham | Buy | Maintains | $N/A | |
| Nov 14, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 6, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 6, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 6, 2025 | Mizuho | Outperform | Maintains | $N/A |
Establishment Labs Holdings Inc. (ESTA) Competitors
The following stocks are similar to Establishment Labs based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ESTA
Establishment Labs
mkt cap
2.59B
Establishment Labs Holdings Inc. (ESTA) Financial Data
Establishment Labs Holdings Inc. has a market capitalization of $2.55B with a P/E ratio of -50.3x. The company generates $229.58M in trailing twelve-month revenue with a -19.1% profit margin.
Revenue growth is +44.7% quarter-over-quarter, while maintaining an operating margin of -10.9% and return on equity of -164.0%.
Valuation Metrics
Market Cap
$2.55B
Enterprise Value
$2.78B
P/E Ratio
-50.3x
PEG Ratio
1.4x
Price/Sales
11.0x
Growth & Margins
Revenue Growth (YoY)
+44.7%
Gross Margin
+70.7%
Operating Margin
-10.9%
Net Margin
-19.1%
EPS Growth
+44.7%
Financial Health
Cash/Price Ratio
+2.7%
Current Ratio
3.0x
Debt/Equity
1,785.5x
ROE
-164.0%
ROA
-5.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Establishment Labs Holdings Inc. (ESTA) Business Model
About Establishment Labs Holdings Inc.
What They Do
Manufactures medical devices for plastic surgeries.
Business Model
The company generates revenue by manufacturing and selling silicone gel-filled breast implants and body-shaping implants, primarily under the Motiva Implants brand. It distributes its products directly to healthcare professionals and through medical distributors across various global regions.
Additional Information
Founded in 2004 and headquartered in Austin, Texas, the company focuses on innovative technologies for aesthetic and reconstructive procedures. Its key markets include Europe, Latin America, and Asia-Pacific, positioning it as a significant player in the medical devices sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
1,004
CEO
Mr. Fillipo Peter Caldini
Country
United States
IPO Year
2018
Website
www.establishmentlabs.comEstablishment Labs Holdings Inc. (ESTA) Latest News & Analysis
Latest News
A Hedge Fund Dumped Establishment Labs Shares Worth $6.6 Million. Here's a Closer Look at the Transaction.
10 days ago
Quick Summary
JW Asset Management sold 90,533 shares for ~$6.64 million at ~$73.31 per share, reducing indirect holdings by 3.04% from ~2.98 million to ~2.89 million shares.
Why It Matters
Insider selling can signal reduced confidence in a company's future prospects, potentially influencing market perception and stock price.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) appointed Taylor Harris to its Board of Directors. He has 25+ years of experience in corporate finance and healthcare leadership.
Why It Matters
The appointment of Taylor Harris to Establishment Labs' board enhances governance and strategic oversight, potentially boosting investor confidence and company performance in the healthcare sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will join the Russell 2000® Index effective June 29, 2026, enhancing its visibility among investors in small-cap stocks.
Why It Matters
Establishment Labs' inclusion in the Russell 2000 Index enhances visibility and credibility, likely attracting institutional investment and potentially boosting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Route 92 Medical appointed Raj Denhoy as CFO, effective May 18, 2026, to strengthen its position in neurovascular intervention.
Why It Matters
The appointment of Raj Denhoy as CFO signals potential strategic financial leadership and growth for Route 92 Medical, impacting investor confidence and company valuation in the medical tech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Establishment Labs Holdings Inc. (ESTA) held its Q1 2026 earnings call, discussing financial performance and strategic updates. Further details can be accessed in the full transcript.
Why It Matters
Q1 earnings calls provide insights into a company’s financial health, growth prospects, and management strategies, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported Q1 2026 revenue of $59.9 million, a 44.7% increase from Q1 2025, and raised guidance to $266.5-$268.5 million.
Why It Matters
Establishment Labs' strong revenue growth and raised guidance signal robust demand for its products, indicating potential for future profitability and positive market sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ESTA Stock
What is Establishment Labs Holdings Inc.'s (ESTA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Establishment Labs Holdings Inc. (ESTA) has a median price target of $92.00. The highest price target is $105.00 and the lowest is $84.00.
Is ESTA stock a good investment in 2027?
According to current analyst ratings, ESTA has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $86.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ESTA stock?
Wall Street analysts predict ESTA stock could reach $92.00 in the next 12 months. This represents a 6.2% increase from the current price of $86.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Establishment Labs Holdings Inc.'s business model?
The company generates revenue by manufacturing and selling silicone gel-filled breast implants and body-shaping implants, primarily under the Motiva Implants brand. It distributes its products directly to healthcare professionals and through medical distributors across various global regions.
What is the highest forecasted price for ESTA Establishment Labs Holdings Inc.?
The highest price target for ESTA is $105.00 from at , which represents a 21.3% increase from the current price of $86.59.
What is the lowest forecasted price for ESTA Establishment Labs Holdings Inc.?
The lowest price target for ESTA is $84.00 from at , which represents a -3.0% decrease from the current price of $86.59.
What is the overall ESTA consensus from analysts for Establishment Labs Holdings Inc.?
The overall analyst consensus for ESTA is bullish. Out of 3 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $92.00.
How accurate are ESTA stock price projections?
Stock price projections, including those for Establishment Labs Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 3:01 AM UTC